康乃德生物医药 CNTB 深 沪
等待开盘 07-01 09:30:00 美东时间
2.38
0.000
0.00%
华盛通- 最 高2.48
- 今 开2.40
- 成交量 59.18万股
- 最 低 2.37
- 昨 收 2.38
- 总市值 1.50亿
- 52周最高 3.82
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 1.23
- 委 比 -9.56%
- 总股本 6296.39万
- 历史最高 29.274
- 量 比 0.80
- 振 幅 4.62%
- 历史最低 0.51
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多分析师解读医疗健康企业：CG Oncology, Inc.（CGON）、阿尔尼拉姆制药（ALNY）与Connect Biopharma Holdings（CNTB）
医疗保健领域释放乐观信号，3名分析师分别对CG肿瘤公司（CGON）、阿尔尼拉姆制药（ALNY）、康奈生物医药控股（CNTB）发布看好评级。 核心标的相关评级与市...
06-30 21:06
美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级
今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元
06-29 15:49
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
06-25 20:50
Connect Biopharma Completes Enrollment In Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart As Adjunct To Standard Of Care For Acute Exacerbations In Asthma And Type 2 Inflammation
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Hold...
06-17 21:02
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Connect Biopharma announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart, an anti-IL-4Rα antibody, for acute asthma exacerbations. The company expects to report topline data in early September 2026 and plans to complete enrollment in its Seabreeze STAT COPD study this month. With a strong balance sheet, Connect aims to meet with the FDA later this year to discuss Phase 3 plans. Rademikibart targe...
06-17 13:00
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
Cantor Fitzgerald Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight rating and announces Price Target of $4.
05-21 22:12
Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.43 percent. This is a 78.95 percent decrease over losses of $(0.19) per
05-12 21:06
